Multicentre survey of diagnostic reference levels for single-photon emission computed tomography/computed tomography...

Diagnostic reference levels (DRLs) are essential indicators for optimising medical radiation exposure, although implementation varies by country. In Japan, the Association of Radiological Technologists in National University Hospitals (ARTNU) investigated baseline DRLs for nuclear medicine based on a nationwide survey, referring to Japan DRLs 2020. These include the 50 th and 75 th percentile values, providing practical benchmarks for administered activity management. However, comparative insights with Japan DRLs 2025 and international standards remain limited.

This nationwide survey, conducted across 42 Japanese national university hospitals, examined radiopharmaceutical and computed tomography (CT) dose indices in single-photon emission computed tomography/CT (SPECT/CT) and positron emission tomography/CT (PET/CT) examinations and compared the results with Japan DRLs 2020; Japan DRLs 2025; and international benchmarks from the UK, Europe, USA, Korea, Australia, and Thailand. Japan DRLs 2025 introduced procedural refinements and anatomy-based CT classifications, particularly for PET/CT, aligning with evolving clinical protocols.

Data on radiopharmaceutical administered activities and CT parameters (CT dose index volume, dose length product) were collected. 18 F-fluorodeoxyglucose-PET protocols predominantly applied 4.0 MBq/kg weight-based dosing, whereas SPECT/CT uses fixed radiopharmaceutical administered activities. CT dose was adapted according to imaging purpose and anatomical region, frequently achieving low-dose operation. Although ARTNU DRLs 2020 remained clinically useful, they exhibited broader administered activity distributions and lack anatomical specificity.

ARTNU DRLs 2020 should be revised with a follow-up survey to better reflect current practices and align with the increased granularity of Japan DRLs 2025. Japanese institutions have demonstrated concordance with global standards and ongoing optimisation of radiopharmaceutical administered activity and CT dose indices through technological advancements.